Half of men with prostate cancer (PC) had poor control of modifiable cardiovascular (CV) risk factors, according to results of a study published in JACC: CardioOncology.

Cardiovascular morbidity and mortality are commonly associated with prostate cancer. Despite the association, there have been few studies evaluating CV risk factor control in the setting of prostate cancer.

This study was designed to evaluate CV trends among a population of patients with prostate cancer. Data were sourced from the Role of Androgen Deprivation Therapy In Cardiovascular Disease – A Longitudinal Prostate Cancer (RADICAL-PC) study. For the study, 2811 patients who were within 1 year of a prostate cancer diagnosis were recruited at sites in 4 countries. Five CV risk factors were assessed: low-density lipoprotein cholesterol, blood pressure, waist-to-hip ratio, current smoking, and physical inactivity.

Continue Reading

The patients were mean age 68.3±8.0 years, 90% were White, and 23% had preexisting CV disease.

Overall, 51% of men had 3 or more poorly controlled CV risk factors. The group at greater CV risk were older (P <.001) and fewer had preexisting CV disease (P =.013) compared with those who had better-controlled CV risk factors.

Patients with 3 or more poorly controlled CV risk factors were more likely to not be taking statins (odds ratio [OR], 2.55), be frail (OR, 2.37), need blood pressure medication (OR, 2.36), and be older (OR, 1.34 per 10-year increase).

Of note, preexisting CV disease was associated with decreased risk for having 3 or more poorly controlled CV risk factors (OR, 0.66).

Findings were consistent in the sensitivity analysis.

The major limitation of this study was that most data were collected from a high-income country and no patients were recruited from low-income countries.

These study findings show that half of patients with prostate cancer had poor control of multiple CV risk factors, indicating a gap in care for this patient population.

Disclosure: Some authors declared affiliations with biotech, pharmaceutical, and/or device companies. Please see the original reference for a full list of disclosures.


Klimis H, Pinthus JH, Aghel N, et al. The burden of uncontrolled cardiovascular risk factors in men with prostate cancer: a RADICAL-PC analysis. JACC CardioOncol. 2023;5(1):70-81. doi:10.1016/j.jaccao.2022.09.008